Our study revealed a high level of SSTR2 expression in the NET G3 group and a higher prevalence of TP53 missense mutation in the NEC group than in the NET G3, which is consistent with previous research findings (19). This evidence concerns the gene TP53 and neuroendocrine carcinoma.